[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-covid-19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-covid-19":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,70,97,121,149,187,220,249,274],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100589939","phase-3-low-dose-sirolimus-in-people-with-post-acute-sequelae-of-covid-19-pasc-long-covid-19-100589939",false,"NCT06960928","Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Any sex, aged 18+\n* Must be able to attend all study visits located at 5 East 98th St, New York, NY\n* Diagnosed with:\n\n  * Long COVID\n\n    * Documented clinical history of confirmed or suspected acute SARS-CoV-2 infection a minimum of 6 months prior to contact with the study team\n    * Formal diagnosis of Long COVID from a physician\n    * At least a six-month history of one of the following symptoms following SARSCoV-2 infection:\n\n      * headache, memory loss, insomnia, mood disturbance, chest pain, palpitations, shortness of breath, cough, muscle pains, joint pains, or GI upset\n      * AND at least moderate fatigue (measured by Fatigue Severity Score)\n      * AND at least moderate post-exertional malaise (PEM) (measured by DePaul PEM screener)\n      * Participants who are willing and able to comply with all data collection, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.\n      * Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected before randomization as part of the baseline survey)\n\nExclusion Criteria:\n\n* Pre-existing conditions including, but not limited to:\n\n  * Autoimmune conditions such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.\n  * A pre-2020 diagnosis of another Post-Acute Infectious Syndrome such as Chronic Lyme disease, Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome, etc.\n  * Documented history of vaccine injury\n  * History of lung or liver transplant\n  * Known hepatic or renal impairment\n  * Weighing less than 40 kg\n  * Or any other chronic condition that has the potential to impact on immunological profiling, at the discretion of the research physician\n* Current use of sirolimus\n* Taking a medication with known interactions to sirolimus:\n\n  * Strong CYP3A4 Inhibitors - clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir, such that dose reduction may be necessary\n  * Strong CYP3A4 Inducers - carbamazepine, dexamethasone, ethosuximide, glucocorticoids, griseofulvin, phenytoin, primidone, progesterone, rifabutin, rifampin, nafcillin, nelfinavir, nevirapine, oxcarbazepine, phenobarbital, phenylbutazone, rofecoxib (mild), St John's wort, sulfadimidine, sulfinpyrazone, troglitazone, and grapefruit, such that dose increase may be necessary.\n  * Drugs that may increase concentration when given with sirolimus - Verapamil, such that dose reduction may be necessary\n  * Other drugs that have the potential to increase sirolimus blood concentrations include (but are not limited to): fluconazole, clotrimazole, troleandomycin, nicardipine, cisapride, and metoclopramide\n  * Concomitant use of angiotensin-converting enzyme (ACE) inhibitors may increase the risk of developing angioedema.\n* Febrile illness within the last 3 months of planned baseline evaluation\n* Treatment with another investigational drug or other investigational intervention within 3 months of planned baseline evaluation\n* Prophylactic use of aspirin (325 mg daily) for cardiovascular indications will be permitted in participants. All other medications for chronic medical conditions should be initiated at least two months prior to enrollment.\n* Uncontrolled diabetes, unstable ischemic heart disease, clinically significant underlying pulmonary disease, history of an immunodeficiency or receiving immunosuppressive therapy; history of coagulopathy or medication condition requiring long-term anticoagulation; history of hepatic impairment; taking angiotensin-converting enzyme (ACE) inhibitors\n* Participants who are planning to be or are pregnant\n* Participants who are nursing","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai.\n\nThis is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo.\n\nThis study aims to evaluate the efficacy of Sirolimus in adults with Long COVID. Efficacy will be evaluated by measuring patient-reported outcomes in response to Sirolimus.",[25],"Long COVID-19",[25,27,28,29],"Post-Acute Sequelae of COVID-19 (PASC)","Sirolimus","Rapamycin","RECRUITING","2026-05-14",{"date":33,"type":34},"2026-05-18","ACTUAL",{"date":36,"type":34},"2025-04-18",{"date":38,"type":19},"2027-05-31",{"name":40,"class":41},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100602455","phase-2-a-study-to-examine-anktiva-for-the-treatment-of-covid-19-100602455","NCT07123727","A Study to Examine Anktiva for the Treatment of COVID-19.","Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID","Inclusion Criteria:\n\n* Age ≥ 18 and \\\u003C 70 years.\n* History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and\u002For a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Those with only suspected but unconfirmed infections are not eligible for this study.\n* Clinical evidence of Long COVID, as confirmed by the Investigator's assessment.\n\n  1. At least 2 symptoms or at least 1 severe symptom as assessed by the study team (see list) that are new or worsened since the time of a SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the PI. At least 2 symptoms from those listed here must be present: systemic symptoms (eg, fatigue, chills, post-exertional malaise), neurocognitive symptoms (eg, trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia symptoms, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (eg, chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (eg, muscle aches, joint pain), gastrointestinal symptoms (eg, nausea, diarrhea). Although other symptoms (eg, skin rash, hair loss, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least 2 core symptoms listed above must be present. Note: the 2 symptoms can be from within the same category (for example, brain fog and headache) AND\n  2. Symptoms must have been present for at least 60 days prior to screening. Symptoms that wax and wane must have been initially present at least 60 days prior to screening AND\n  3. Symptoms must be reported to be at least somewhat bothersome and to have an impact on quality of life and\u002For everyday functioning AND\n  4. At least 90 days have elapsed since the most recent suspected or confirmed SARS-CoV-2 infection and the time of screening. Note: suspected infections will be determined based upon assessment by the study Investigators.\n* Not currently hospitalized.\n* Body mass index (BMI) 18 to 50 kilograms\u002Fmeter squared (kg\u002Fm2), inclusive, at the time of screening.\n* In otherwise stable health, as assessed by the Investigator within 28 days prior to screening, based on medical history, physical examination, laboratory findings, and vital signs.\n* For male participants,\n\n  a. Participants with partners that are WOCBP are strongly advised to inform their partners and must agree to use effective contraception from study entry (defined as INT1) through 7 months after the last dose of study intervention. Participants with pregnant partners must agree to use condoms during vaginal intercourse from study entry (defined as INT1) through 14 days after the last dose of study intervention administration.\n* For female participants,\n\n  a. A female participant who engages in sexual intercourse with male partners is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies: i. Is not a WOCBP OR ii. All of the following apply:\n  1. Is a WOCBP and is using a contraceptive method from - 21 days from study entry (defined as INT1), during the study intervention period, and for at least 7 months after the last study intervention administration.\n  2. A WOCBP must have a negative urine pregnancy test within 24 hours prior to all doses of study intervention. If a urine pregnancy test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test must be negative.\n* Willingness and ability to comply with the study protocol. This includes reliable transportation and sufficient time to attend all visits.\n* Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Previously received a SARS-CoV-2 antiviral or monoclonal antibody 30 days prior to planned INT1 or plan to receive such treatment before exiting the study.\n* Plans to receive any investigational or approved vaccine or booster for SARS-CoV-2 within 14 days prior to plan to receive such treatment before exiting the study.\n* History of autoimmune disease including, but not limited, to celiac disease, rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.\n* Active cardiovascular disease, defined as known prior:\n\n  1. Myocardial infarction within 90 days of screening; OR\n  2. Coronary artery bypass procedure within 90 days of screening; OR\n  3. Current heart failure with reduced ejection fraction (\\\u003C45%); OR\n  4. Current pulmonary arterial hypertension.\n* Known stroke within 3 months prior to planned INT1.\n* Known active bacterial, fungal, viral, or other infection besides SARS-CoV-2 requiring treatment within the 14 days prior to INT1 and meeting criteria for systemic involvement upon review by the PI.\n* Major surgery within 3 months prior to planned INT1 or planned major surgery during the first 75 days following planned INT1.\n* History of unplanned hospitalization for \\>24 hours within 28 days prior to Screening.\n* Active or prior Hepatitis B (Hep B) infection (defined as Hep B core antibody (cAb) and\u002For Hep B surface antigen (sAg) positive. Note: Prior hepatitis B is exclusionary even in the absence of ongoing infection.\n* Active Hepatitis C (Hep C) infection (defined as Hep C Ab positive or indeterminate with detectable Hep C RNA). Note: Those with cured Hep C (Ab positive or indeterminate but negative Hep C RNA) will remain eligible.\n* Laboratory abnormalities including:\n\n  1. ANC \\\u003C 1,500 per mm3\n  2. Platelet count \\\u003C100,000 per mm3\n  3. Hemoglobin \\\u003C 9 d\u002FdL\n  4. Baseline AST or ALT \\> 1.5 × ULN\n  5. CrCl \\\u003C 50 (estimated glomerular filtration rate)\n* Known or suspected HIV infection.\n* End stage kidney disease requiring dialysis.\n* History of Type I or Type 2 Diabetes mellitus requiring systemic medication or insulin.\n* Severe hepatic impairment (Child-Pugh Class C).\n* Moderate or severe immunocompromise, includes the following: (a) receiving active treatment for solid tumor or hematologic malignancy, including use of systemic chemotherapy for treatment of cancer within the year prior to screening, (b) prior solid-organ transplant with active immunosuppressive therapy, (c) CAR-T cell therapy or hematopoietic cell transplant, on immunosuppressive therapy or transplant within the prior 2 years, (d) primary immunodeficiency syndromes, advanced or untreated HIV infection (see above), (f) on active high-dose corticosteroids (ie, ≥ 20mg prednisone or equivalent daily per day for ≥ 2 weeks).\n* Known prior diagnosis of myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS), preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known prior diagnosis of dysautonomia, preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known allergy to any components used in the formulation of the intervention.\n* History of anaphylaxis or similar significant allergic reaction to prescription or non-prescription drugs or food products. Similarly, the presence of severe atopic conditions as assessed by the PI represents a significant risk for allergic reaction.\n* Participation in a clinical trial with receipt of an investigational product within 28 days prior to planned INT1, except for exploratory PET imaging studies related to Long COVID.\n* Current alcohol or illicit drug use as determined by the Investigator to preclude participation.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.","70 Years",{"count":52,"type":19},40,[54],"PHASE2","This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.",[57,58,59],"Long COVID","Long COVID Syndrome","Long Covid 19","2026-05-08",{"date":62,"type":34},"2026-05-13",{"date":64,"type":34},"2025-09-04",{"date":66,"type":19},"2026-07",{"name":68,"class":69},"ImmunityBio, Inc.","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100468421","long-covid-comorbidities-andrological-reproductive-sexual-dysfunctions-in-patients-recovered-from-covid-19-100468421","NCT05379556","LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19","LOng COvid COmorbidities: Evaluation of Andrological, Reproductive and Sexual Functions in Patients Recovered From COVID-19","Inclusion Criteria:\n\n* Patients of both sexes recovered from SARS-CoV-2 infection (two negative nasopharyngeal swabs, negative IgM and positive anti SARS-CoV-2 IgG);\n* Aged over 18 years of age;\n* Ability to understand protocol procedures\n\nExclusion Criteria:\n\n* Any psychological\u002Fpsychiatric\u002Fother medical conditions compromising the understanding of the nature and purpose of the study, and of its possible consequences\n* Uncooperative attitude of the patient",{"count":78,"type":19},100,"OBSERVATIONAL","Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the purpose of the study is to investigate, in patients recovered from COVID-19 disease: 1) whether SARS-CoV-2 infection has induced in male patients, a primary (testicular) and \u002F or secondary (pituitary) damage to the hypothalamic-pituitary-testicular hormonal axis, structural and \u002F or functional damage to the testis and penis, sexual dysfunction or fertility disorders; 2) the prevalence in male and female patients of chemosensory symptoms (olfactory dysfunction) and assess whether there is a correlation between the prevalence, severity, duration and eventual persistence of olfactory dysfunction and the severity of COVID-19 disease. Patients will be evaluated at baseline (at discharge from infectious and\u002For pneumology unit) and after 3- 12 months. A better definition of the prevalence and type of sequelae after recovery from COVID-19 disease could significantly improve the therapeutic management and long-term follow-up of these patients, with a relevant impact in terms of health resources and public health.",[82],"Long Covid-19",[82,84,85,86,87],"Andrological complications","Reproductive complications","Sexual complications","Olfactory complications","2025-08-08",{"date":90,"type":34},"2025-08-11",{"date":92,"type":34},"2022-01-27",{"date":94,"type":19},"2027-01-27",{"name":96,"class":41},"Federico II University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":120,"locationsCount":42},"100461800","long-covid-comorbidities-endocrinemetabolicneuropsychiatricmusclecardiovascularpulmonarydermatologic-dysfunctions-100461800","NCT05293366","LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions","LOng COvid COmorbidities: Evaluation of Endocrine, Metabolic, Neuropsychiatric, Muscle, Cardiovascular, Pulmonary and Dermatologic Functions","LO-COCO","Inclusion Criteria:\n\n* Patients of both sexes recovered from SARS-CoV-2 infection (two negative nasopharyngeal swabs, negative IgM and positive anti SARS-CoV-2 IgG);\n* Aged over 18 years of age;\n* Ability to understand protocol procedures\n\nExclusion Criteria:\n\n* Any psychological\u002Fpsychiatric\u002Fother medical conditions compromising the understanding of the nature and purpose of the study, and of its possible consequences\n* uncooperative attitude of the patient",{"count":78,"type":19},"Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of SARS-CoV-2 infection, the purpose of the study is to investigate whether in patients recovered from COVID-19 disease, SARS-CoV-2 infection has induced: 1) endocrine-metabolic function damage; 2) neuro-psychiatric damage; 3) muscle damage; 4) pulmonary damage; 5) cardiological damage; 6) venous vascular damage; 7) dermatological damage. Patients will be evaluated at baseline (at discharge from infectious and\u002For pneumology unit) and after 3- 12 months. A better definition of the prevalence and type of sequelae after recovery from COVID-19 disease could significantly improve the therapeutic management and long-term follow-up of these patients, with a relevant impact in terms of health resources and public health.",[82],[82,109,110,111,112,113,114,115],"Endocrine Complications","Metabolic Complications","Neuropsychiatric Complications","Muscular Complications","Cardiovascular Complications","Pulmonary Complications","Dermatologic Complications","2025-08-07",{"date":88,"type":34},{"date":92,"type":34},{"date":94,"type":19},{"name":96,"class":41},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":20,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":42},"100528085","pursuing-reduction-in-fatigue-after-covid-19-via-exercise-and-rehabilitation-prefacer-a-randomized-feasibility-trial-100528085","NCT06156176","Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial","PREFACER","Inclusion Criteria:\n\n* Adults of at least 18 years of age\n* Able to provide informed consent\n* Can speak and understand English\n* Documented history of SARS-CoV-2 infection (positive PCR\u002Fantigen test during acute illness or clinical diagnosis by physician during or after the acute illness)\n* Fatigue symptoms within 3 months of COVID-19 infection, lasting at least 2 months\n* Fatigue symptoms cannot be explained by an alternative diagnosis\n* Fatigue symptoms may be new onset following initial recovery from an acute COVID-19 infection or persist from the initial illness\n* Fatigue symptoms may have an episodic nature, fluctuate or relapse over time\n* Minimal functional capability: able to walk 10-15 minutes and be recovered within 30-60 minutes or without significant post-exertional malaise (PEM)\n* Has applicable technology to access Microsoft Teams and Webex (i.e., computer, laptop, tablet)\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\n* Pre-existing physical, cognitive, and\u002For mental health conditions that make exercise contraindicated, consent unattainable, or that cause symptoms similar to those seen in post COVID-19 (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome) that could affect data\n* Inability to follow study procedures\n* Pregnant and\u002For breastfeeding\n* Received investigational agents as part of a separate study within 30 days of the screening visit\n* Has any type of metal bodily implant in head or heart (i.e., pins, plates, pacemakers)\n* Current participation in other studies related to COVID-19, exercise, and\u002For fatigue interventions OR participation within 30 days of the screening visit",{"count":129,"type":19},60,[131],"NA","Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants will be recruited, randomly assigned to the COVIDEx program or standard of care (SoC) and followed for 24 weeks.",[134,25,135,136,137,138,139],"Long-COVID","Post-COVID-19 Syndrome","Post-COVID Syndrome","Fatigue","Post COVID-19 Condition","Post-COVID Condition","2025-07-29",{"date":142,"type":34},"2025-08-01",{"date":144,"type":34},"2025-04-01",{"date":146,"type":19},"2026-04-01",{"name":148,"class":41},"Lawson Research Institute of St. Joseph's",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":15,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":20,"phases":161,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100599076","telerehabilitation-decision-support-system-pilot-testing-protocol-100599076","NCT07079787","Telerehabilitation Decision Support System: Pilot Testing Protocol","Telerehabilitation of Balance Clinical and Economic Decision Support System","TeleRehab DSS","ALL PARTICIPANT Inclusion Criteria:\n\n* Age 40-80 years\n* community dwelling able to walk 500-m independently or with a stick\n* Depression subscale on Hospital Anxiety and Depression Scale \\\u003C10\u002F21 (14-item questionnaire)\n* No significant visual impairment (as self-reported by participants)\n* Willing to comply with study procedures, proposed training and testing regime\n* With capacity to consent\n* No acute musculoskeletal or other injuries that would prevent participation in a structured exercise program\n* Is not currently, and has not in the past 8-weeks received any falls\u002Fbalance\u002Fvestibular and\u002For cognitive rehabilitation.\n* Does not any implanted medical devices or a cardiac pacemaker.\n* Does not have any other co-existing neurological conditions (ie. Multiple sclerosis, Parkinson's disease, neuropathy etc.)\n* Does not have any language or communication deficits impairing their ability to communicate and\u002For express their thoughts.\n* Has at least one functional hand for grip function and computer use.\n* Fulfilling all of the criteria from one of the below sub-groups\n\nSTROKE COHORT who will fulfil the additional criteria:\n\n* Individuals with diagnosis of focal ischaemic or haemorrhagic stroke, as confirmed by a clinical letter.\n* Onset \\>\u002F= 3 months prior to study.\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* At risk of falls (i.e. Functional Gait Assessment FGA score \\\u003C\u002F=22\u002F30; FGA is a validated quick balance task assessment) AND\u002FOR having experienced a fall(s) in the last 12 months\n\nMCI COHORT who will fulfil the additional criteria:\n\n* Individuals with new or existing formal diagnosis of MCI, according to the International Classification of Disease 10 (ICD10) , as confirmed by a clinical letter.\n* At risk of falls (FGA \\\u003C\u002F= 22\u002F30) AND\u002FOR having experienced a fall(s) in the last 12 months.\n\nVESTIBULAR COHORT who will fulfill the additional criteria\n\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* Individuals with a diagnosis of a vestibular disorder (peripheral and\u002For mixed peripheral and central):\n* Peripheral vestibular disorder in which the balance problem lies in the vestibular\u002Fbalance system within the inner ear.\n* Mixed vestibular disorder in which the balance problem lies in the vestibular\u002Fbalance system within the inner ear (peripheral) and involving the nerves or neuronal network in the brain\u002Fbrainstem responsible for balance (central).\n* Chronic dizziness and\u002For unsteadiness (\\>\u002F= 3 months duration) that started at the time or after the vestibular disorder diagnosis.\n* Dizziness handicap inventory (DHI \\>34) AND\u002FOR At risk of falls (FGA \\\u003C\u002F=22\u002F30)\n\nLONG COVID-19 COHORT who will fulfill the additional criteria:\n\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* Individuals with laboratory confirmed diagnosis of Covid (\\>\u002F=6 months prior to study onset), as confirmed by a clinical letter.\n* Who have been diagnosed with long Covid, as confirmed by a clinical letter.\n* Who have chronic dizziness and\u002For unsteadiness which started after the Covid illness (self-report by the patient; duration \\\u003C\u002F=3 months).\n* Dizziness handicap inventory (DHI \\>34) AND\u002FOR At risk of falls (FGA \\\u003C\u002F=22\u002F30)\n\nExclusion Criteria:\n\n* Outside of the stated age bracket\n* Unable to walk independently (even with use of a walking stick)\n* MOCA score \\\u003C23\n* Score of 10 or higher on depression subscale of HADS\n* Unwilling to comply with study procedures, proposed training and testing regime\n* No capacity to consent\n* Significant visual impairment or homonymous hemianopia (stroke cohort only) (self-reported)\n* Orthostatic hypotension or uncontrolled hypertension\n* Other neurological problem (e.g. Parkingson's disease, Multiple Sclerosis etc.)\n* Language and communication deficits impairing ability to express thoughts (e.g. Aphasia)\n* Has participated in a clinical drug trial in the past 6 months.\n* Acute musculoskeletal injury that prevents participation in a structured exercise programme (e.g. lower limb fracture).\n* Has an implanted medical device or cardiac pacemaker.\n* Diagnosis of unstable Meniere's or with more than 4 migraines\u002Fmonth at the time of participating in the study\n* Not fulfilling the inclusion criteria for one of the sub-groups (such as criteria for Stroke group, or MCI group, or chronic vestibular disorder group, or long-Covid group), as outlined above.\n* Unable to provide a clinical letter confirming diagnosis.\n* For those with stroke, no visual spatial neglect.","40 Years","80 Years",{"count":160,"type":19},30,[131],"This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. Further information is available at: https:\u002F\u002Fholobalance.eu\u002F. HOLOBalance was developed as a comprehensive rehabilitation protocol for individualised remote (tele)rehabilitation balance physiotherapy programme. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.\n\nThis pilot testing of a multisite randomised control trial (TeleRehab DSS, short for TeleRehabilitation Decision Support System) aims to investigating the usability and feasibility among a smaller sample population at each clinical site, identifying any technical bugs, and\u002For clinical procedural flaws to be remedied before delivery of the full-scale RCT.",[164,165,166,82],"Stroke","Mild Cognitive Impairment (MCI)","Vestibular Disease",[168,169,170,171,172,173,174,175],"vestibular","rehabilitation","falls","balance","exercise","artificial intelligence","teleremedicine","physiotherapy","NOT_YET_RECRUITING","2025-07-18",{"date":179,"type":34},"2025-07-23",{"date":181,"type":19},"2025-07-25",{"date":183,"type":19},"2025-08-29",{"name":185,"class":41},"University College, London",5,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":20,"phases":196,"briefSummary":197,"conditions":198,"keywords":203,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100587445","effectiveness-and-acceptability-of-the-unified-protocol-for-the-transdiagnostic-treatment-of-emotional-disorders-in-people-with-long-covid-19-100587445","NCT06928480","Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.","UP-LONGCOVID-R","Inclusion Criteria:\n\n* Residing in Autonomous Community of Aragon (Spain).\n* Being at least 18 years old.\n* Understanding of Spanish.\n* Being diagnosed with long COVID-19: documented SARS-CoV-2 infection and persistence of symptoms beyond 12 weeks after the acute infection.\n* Symptoms of depression (ODSIS≥7) and\u002For anxiety (OASIS≥8).\n* Meeting the criteria for an emotional disorder diagnosis.\n* Having access to Internet.\n* Signing the informed consent.\n\nExclusion Criteria:\n\n* Pre-existing emotional symptoms prior to the acute SARS-CoV-2 infection.\n* Actually receiving psychological treatment.\n* Having a diagnosis of severe mental disorder (e.g., personality disorder, bipolar disorder, etc.).\n* Active suicidal ideation at the time of the assessment.\n* Individuals on psychotropic medication must maintain their dosage throughout the study, unless medically contraindicated.",{"count":195,"type":19},90,[131],"This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited at Hospital Royo Villanova from Zaragoza, Spain.\n\nIn this study it will be explored whether the changes obtained after the intervention in emotional disorders and cognitive complaints are maintained over 12 months. Additionally, levels of chronic stress will be longitudinally evaluated in the experimental group through accumulated cortisol levels in hair, before and after the application of the UP.",[82,199,200,201,202],"Emotional Disorder","Anxiety","Depression Disorders","Emotion Regulation",[25,204,205,206,207,208,209],"Emotional Disorders","Emotion regulation skills","Unified Protocol","Transdiagnostic","Psychological","Cognitive Behavioral","2025-05-19",{"date":212,"type":34},"2025-05-22",{"date":214,"type":34},"2025-05-01",{"date":216,"type":19},"2026-12-31",{"name":218,"class":41},"Instituto de Investigación Sanitaria Aragón",2,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":15,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100586138","from-inflammation-to-remodelling-towards-personalized-diagnosis-in-post-acute-sequelae-of-covid-19-100586138","NCT06911476","From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","From Inflammation Biomarkers to Remoddeling (FAPI PET\u002FCT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","LIBERATE","Inclusion Criteria:\n\n\\- Self-reported complaints of dyspnea or fatigue \\> 3 months after SARS-CoV-2 infection confirmed with PCR, serology test or COVID-19 Reporting and Data System (CO-RADS) score 4\u002F5.\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or feeling of inability to tolerate supine position for the PET\u002FCT scans.\n* Individuals who are pregnant or currently breastfeeding are not eligible to participate",true,"20 Years",{"count":129,"type":19},"Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that \\[68Ga\\]FAPI Positron Emission Tomography-Computed Tomography (PET\u002FCT) imaging shows potential for diagnosis and molecular understanding of this syndrome. We have previously shown that fibroblast activation protein (FAP) can be imaged in the lung, muscle and nasopharynx of long COVID patients (with dyspnea and fatigue). However, these preliminary data are derived from a selective group of patients with long COVID after critical COVID-19. We aim to explore the generalizability of these findings in patients with long COVID with dyspnea and fatigue, irrespective of the severity of their acute SARS-CoV-2 infection.\n\nPrimary objective: To assess if pulmonary fibroblast activity, measured by \\[68Ga\\]FAPI-46 PET\u002FCT, is higher in patients with current long COVID dyspnea and fatigue compared to patients with resolved complaints.\n\nStudy design: This is a ZonMw funded single centre prospective observational cohort study of long COVID-19 patients with dyspnea and fatigue.\n\nStudy population: We will recruit 60 adult long COVID patients (aged \\>20 years) of which 30 have complaints of dyspnea and fatigue and compare them to 30 patients with resolved complaints and healthy controls.\n\nMain study parameters\u002Fendpoints: The primary endpoint is FAP expression in the lung measured by \\[68Ga\\]FAPI-46 PET\u002FCT. Secondary endpoints are the expression of FAP in other tissues (muscle) and the relation between FAP and inflammation and remodelling biomarkers in various biological samples (e.g. serum\u002Fnasal epithelium).\n\nStudy procedures: In a single visit day the following data and samples will be collected: questionnaires, a lung function test, 6-minute walking test, blood samples, nose swabs, \\[68Ga\\]FAPI PET\u002FCT scan and HRCT scan. When increased \\[68Ga\\]FAPI uptake is measured in the muscles a muscle biopsy will be performed as well.",[233,57,82,234,235,236,237,238,239],"PASC Post Acute Sequelae of COVID 19","PASC","FAPI","FAP","Fibroblast Activation Protein Inhibitor","Fibroblast","Restrictive Lung Disease","2025-04-03",{"date":242,"type":34},"2025-04-04",{"date":244,"type":19},"2025-05",{"date":246,"type":19},"2025-12",{"name":248,"class":41},"University Medical Center Groningen",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":15,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":20,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":42},"100583486","nenca-study-on-neurological-complications-of-long-covid-19-in-children-and-adolescents-neurophysiological-electroencephalographic-and-neuroradiological-investigation-100583486","NCT06876948","NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencephalographic and Neuroradiological Investigation","STUDY of NEUROLOGICAL COMPLICATIONS of LONG COVID-19 in CHILDREN and ADOLESCENTS; NEUROPSYCHIATRIC, ELECTROENCEPHALOGRAPHIC and NEURORADIOLOGICAL INVESTIGATIONS","NENCA","Inclusion Criteria:\n\n* Age between 6 years and 16 years and 11 months\n* Symptomatology compatible with long neurological COVID, specifically: persistence or appearance of new neurological signs\u002Fsymptoms (e.g. fatigue, headache, sleep disturbance, cognitive dysfunction, memory difficulties, emotional or mood disorders, vertigo cognitive dysfunction, memory difficulties, emotional or mood disorders, dizziness, dysautonomia, movement disorders movement disorders, ataxia, tremor, epilepsy, muscle weakness, myalgia, hyposmia, hypogeusia hearing loss or tinnitus and\u002For sensorimotor deficits such as hypoesthesia, dysesthesia) after three months after established SARS-CoV-2 infection, as well as persistence of these symptoms for at least two months, in the absence of a clear aetiology.\n* Signature of the appropriate Informed Consent by caregiver(s) and patient(s)\n\nExclusion Criteria:\n\n* Poor knowledge of the Italian language or other limitation of verbal communication that compromises the subject's ability to perform neuropsychological tests\n* Need for sedation to perform brain MRI 7 Tesla\n* Neurological or neuropsychiatric disorder diagnosed prior to COVID-19 diagnosis\n* Caregiver's failure to sign consent","6 Years","16 Years",{"count":78,"type":19},[131],"The study seeks to investigate the neurological effects caused by Covid-19 in children and adolescents in the 6-16 age group. To do this, neuropsychological scales, an EEG and an MRI were used.",[82],[264],"Covid-19","2025-03-13",{"date":267,"type":34},"2025-03-14",{"date":269,"type":34},"2023-03-29",{"date":271,"type":19},"2026-04-28",{"name":273,"class":41},"Azienda Ospedaliero, Universitaria Pisana",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":281,"targetDuration":282,"studyType":79,"phases":4,"briefSummary":283,"conditions":284,"keywords":290,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":42},"100453913","register-study-implementation-of-pharyngeal-electrostimulation-therapy-for-the-treatment-of-acute-neurogenic-dysphagia-100453913","NCT05190718","Register Study: Implementation of Pharyngeal Electrostimulation Therapy for the Treatment of Acute Neurogenic Dysphagia","R:IphEst","Inclusion Criteria:\n\n* Neurogenic dysphagia\n\n  * Ischaemic and haemorrhagic strokes\n  * Infra- as well as supra-tentorial\n  * Polyradiculitis\n  * Parkinson's disease\n  * Multiple sclerosis\n  * Dementia\n  * Traumatic brain injury\n  * Post Covid-19 pat.\n* patients over the age of 18.\n\nExclusion Criteria:\n\n* Contraindication to nasogastric tube,\n* Unstable cardiac or respiratory condition that does not allow the insertion of the Nasogastric tube\n* Pacemakers\n* Implanted defibrillators (ICD)\n* Pregnant\n* Breastfeeding women\n\n(Caution: interfering signals may be visible in ECGs, \\& EEGs with continuous recording).",{"count":78,"type":19},"90 Days","Neurogenic dysphagia occurs with disruption of neurological systems or processes involved in the execution of coordinated and safe swallowing. It is common in patients with neurological diseases, in particular in patients treated in Intensive Care Units (ICU) who are intubated (up to 62%) and \u002F or tracheotomised (up to 83%). Dysphagia is one of the most common and most dangerous symptoms of many neurological diseases. In addition, neurogenic dysphagia can have a significant impact on quality of life, medication efficacy, and malnutrition.\n\nDysphagia is currently treated conservatively on evidence-based exercises, individually adapted to each patient. In the recent years pharyngeal electrostimulation has been established and shown a positive impact on outcome. In fact, this type of therapy has not only become an addition to the existing therapy, but an important alternative for patients difficult to treat by other means.\n\nThe Phagenyx® is a medical device, which has lately been used more frequently in multiple hospitals for treatment of neurogenic dysphagia. For nearly two decades pharyngeal electrostimulation has been further developed and optimised. This therapy initiates changes in the swallowing motor cortex through neuroplasticity as well as local changes in peripheral sensory architecture associated with swallowing. Bath and colleagues (2020) recently reported the efficacy of pharyngeal electrostimulation (Phagenyx®) in various neurological conditions.\n\nAs a result, of current published studies, the use of pharyngeal electrostimulation probe, in selected patients, with neurological diseases with moderate to severe neurogenic dysphagia will be evaluated.\n\nThis trial will initially start as quality assurance project with the aim to extent it into a monocentric based register study.\n\nThe Investigators aim to validate the effectiveness of pharyngeal electrostimulation for the treatment of moderate to severe neurogenic dysphagia by systematically recording specific dysphagia-relevant parameters. At present, it is still uncertain to what extent patients with neurogenic dysphagia in the context of a non-acute neurological disease could benefit from this method.\n\nThe research questions:\n\nDoes the use of the pharyngeal electrostimulation probe have an influence on the outcome of dysphagia in patients with moderate to severe neurogenic dysphagia? How long after therapy, can the use of the pharyngeal electrostimulation probe lead to oral food intake and\u002For removal of a tracheal cannula?",[285,286,164,287,82,288,289],"Neurogenic Dysphagia","Traumatic Brain Injury","Dysphagia","Intubation Complication","Polyradiculitis",[285,287,286,291,164,292,82],"Phagenyx","Pharyngeal electrical stimulation","2025-03-04",{"date":295,"type":34},"2025-03-07",{"date":297,"type":34},"2021-12-15",{"date":299,"type":19},"2026-12-30",{"name":301,"class":41},"Karl Landsteiner University of Health Sciences"]